New Medicines

Habeo (EU) · Systemic sclerosis (scleroderma); -associated hand dysfunction


Habeo (EU)
Cell-based therapy (not an ATMP)
Cytori Therapeutics
Cytori Therapeutics

Development and Regulatory status

Phase I Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials


Adipose tissue-derived stromal vascular fraction (SVF) as a source of source of regenerative cells with therapeutic potential
Systemic sclerosis (Scleroderma) is present throughout the world and is represented in all ethnic groups. Around 88 patients per million of the UK population are affected with a female:male ratio 4:1. The usual age of onset is 30-50 years, but it can affect any age group. It is rare in children. [1]
Systemic sclerosis (scleroderma); -associated hand dysfunction
Subcutaneous injection

Evidence based evaluations